{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:14:28Z","timestamp":1793038468686,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GEROK Stipend"],"award-info":[{"award-number":["GEROK Stipend"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The European Union's Horizon 2020 research and innovation programme","award":["667273"],"award-info":[{"award-number":["667273"]}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2015.111.1"],"award-info":[{"award-number":["2015.111.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00428-019-02706-6","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T16:02:45Z","timestamp":1576339365000},"page":"871-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["HER2 gene (ERBB2)\u00a0amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma"],"prefix":"10.1007","volume":"476","author":[{"given":"Thomas","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Halske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianeb","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika Nadja","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Pathil-Warth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Heinz","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Goeppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,14]]},"reference":[{"key":"2706_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/CLEP.S37357","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA (2014) Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 6:99\u2013109. https:\/\/doi.org\/10.2147\/CLEP.S37357","journal-title":"Clin Epidemiol"},{"key":"2706_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1479-666X(08)80073-X","volume":"6","author":"CH Lai","year":"2008","unstructured":"Lai CH, Lau WY (2008) Gallbladder cancer--a comprehensive review. Surgeon 6:101\u2013110","journal-title":"Surgeon"},{"key":"2706_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3332\/ecancer.2016.704","volume":"10","author":"L Villanueva","year":"2016","unstructured":"Villanueva L (2016) Cancer of the gallbladder-Chilean statistics. Ecancermedicalscience 10:704. https:\/\/doi.org\/10.3332\/ecancer.2016.704","journal-title":"Ecancermedicalscience"},{"key":"2706_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1158\/1055-9965.EPI-15-0199","volume":"24","author":"SJ Henley","year":"2015","unstructured":"Henley SJ, Weir HK, Jim MA, Watson M, Richardson LC (2015) Gallbladder cancer incidence and mortality, United States 1999-2011. Cancer Epidemiol Biomark Prev 24:1319\u20131326. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0199","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2706_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrc1429","volume":"4","author":"II Wistuba","year":"2004","unstructured":"Wistuba II, Gazdar AF (2004) Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 4:695\u2013706. https:\/\/doi.org\/10.1038\/nrc1429","journal-title":"Nat Rev Cancer"},{"key":"2706_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1634\/theoncologist.2009-0302","volume":"15","author":"AX Zhu","year":"2010","unstructured":"Zhu AX, Hong TS, Hezel AF, Kooby DA (2010) Current management of gallbladder carcinoma. Oncologist 15:168\u2013181. https:\/\/doi.org\/10.1634\/theoncologist.2009-0302","journal-title":"Oncologist"},{"key":"2706_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, Investigators ABCT (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"2706_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","volume":"101","author":"JW Valle","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer 101:621\u2013627. https:\/\/doi.org\/10.1038\/sj.bjc.6605211","journal-title":"Br J Cancer"},{"key":"2706_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12885-018-4575-3","volume":"18","author":"JM Nemunaitis","year":"2018","unstructured":"Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli RR (2018) Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico BMC. Cancer 18:665. https:\/\/doi.org\/10.1186\/s12885-018-4575-3","journal-title":"Cancer"},{"key":"2706_CR10","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469\u20136487. https:\/\/doi.org\/10.1038\/sj.onc.1210477","journal-title":"Oncogene"},{"key":"2706_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","volume":"17","author":"DP English","year":"2013","unstructured":"English DP, Roque DM, Santin AD (2013) HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 17:85\u201399. https:\/\/doi.org\/10.1007\/s40291-013-0024-9","journal-title":"Mol Diagn Ther"},{"issue":"Suppl 1","key":"2706_CR12","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/annonc\/12.suppl_1.S81","volume":"12","author":"S Scholl","year":"2001","unstructured":"Scholl S, Beuzeboc P, Pouillart P (2001) Targeting HER2 in other tumor types. Ann Oncol 12(Suppl 1):S81\u2013S87","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2706_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000055404","volume":"61","author":"S Menard","year":"2001","unstructured":"Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A (2001) HER2 as a prognostic factor in breast cancer. Oncology 61(Suppl 2):67\u201372. https:\/\/doi.org\/10.1159\/000055404","journal-title":"Oncology"},{"key":"2706_CR14","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"2706_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7150\/jca.4090","volume":"3","author":"JT Jorgensen","year":"2012","unstructured":"Jorgensen JT, Hersom M (2012) HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer 3:137\u2013144. https:\/\/doi.org\/10.7150\/jca.4090","journal-title":"J Cancer"},{"key":"2706_CR16","first-page":"42","volume":"7","author":"I Roa","year":"2014","unstructured":"Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M (2014) Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res 7:42\u201348","journal-title":"Gastrointest Cancer Res"},{"key":"2706_CR17","first-page":"221","volume":"1","author":"T Kawamoto","year":"2007","unstructured":"Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, Roa I, Roa JC, Thomas MB (2007) HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer. Gastrointest Cancer Res 1:221\u2013227","journal-title":"Gastrointest Cancer Res"},{"key":"2706_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3748\/wjg.v18.i11.1208","volume":"18","author":"C Toledo","year":"2012","unstructured":"Toledo C, Matus CE, Barraza X, Arroyo P, Ehrenfeld P, Figueroa CD, Bhoola KD, Del Pozo M, Poblete MT (2012) Expression of HER2 and bradykinin B(1) receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol 18:1208\u20131215. https:\/\/doi.org\/10.3748\/wjg.v18.i11.1208","journal-title":"World J Gastroenterol"},{"key":"2706_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0377-4929.94862","volume":"55","author":"N Kumari","year":"2012","unstructured":"Kumari N, Kapoor VK, Krishnani N, Kumar K, Baitha DK (2012) Role of C-erbB2 expression in gallbladder cancer. Indian J Pathol Microbiol 55:75\u201379. https:\/\/doi.org\/10.4103\/0377-4929.94862","journal-title":"Indian J Pathol Microbiol"},{"key":"2706_CR20","doi-asserted-by":"publisher","unstructured":"Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS (2006) Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582. BMC Cancer 6(126). https:\/\/doi.org\/10.1186\/1471-2407-6-126","DOI":"10.1186\/1471-2407-6-126"},{"key":"2706_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/path.1779","volume":"206","author":"K Nakazawa","year":"2005","unstructured":"Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206:356\u2013365. https:\/\/doi.org\/10.1002\/path.1779","journal-title":"J Pathol"},{"key":"2706_CR22","first-page":"815","volume":"11","author":"S Matsuyama","year":"2004","unstructured":"Matsuyama S, Kitajima Y, Sumi K, Mori D, Satoh T, Miyazaki K (2004) Gallbladder cancers rarely overexpress HER-2\/neu, demonstrated by Hercep test. Oncol Rep 11:815\u2013819","journal-title":"Oncol Rep"},{"key":"2706_CR23","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3748\/wjg.15.4511","volume":"15","author":"J Harder","year":"2009","unstructured":"Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG (2009) EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15:4511\u20134517. https:\/\/doi.org\/10.3748\/wjg.15.4511","journal-title":"World J Gastroenterol"},{"key":"2706_CR24","first-page":"1679","volume":"27","author":"H Puhalla","year":"2007","unstructured":"Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Gruenberger T, Tamandl D, Filipits M (2007) Expression of p21(Wafl\/Cip1), p57(Kip2) and HER2\/neu in patients with gallbladder cancer. Anticancer Res 27:1679\u20131684","journal-title":"Anticancer Res"},{"key":"2706_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00428-015-1720-0","volume":"466","author":"AP Moy","year":"2015","unstructured":"Moy AP, Shahid M, Ferrone CR, Borger DR, Zhu AX, Ting D, Deshpande V (2015) Microsatellite instability in gallbladder carcinoma. Virchows Arch 466:393\u2013402. https:\/\/doi.org\/10.1007\/s00428-015-1720-0","journal-title":"Virchows Arch"},{"key":"2706_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00428-015-1898-1","volume":"468","author":"H Yoshida","year":"2016","unstructured":"Yoshida H, Shimada K, Kosuge T, Hiraoka N (2016) A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Arch 468:431\u2013439. https:\/\/doi.org\/10.1007\/s00428-015-1898-1","journal-title":"Virchows Arch"},{"key":"2706_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.humpath.2009.10.002","volume":"41","author":"N Shafizadeh","year":"2010","unstructured":"Shafizadeh N, Grenert JP, Sahai V, Kakar S (2010) Epidermal growth factor receptor and HER-2\/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol 41:485\u2013492. https:\/\/doi.org\/10.1016\/j.humpath.2009.10.002","journal-title":"Hum Pathol"},{"key":"2706_CR28","doi-asserted-by":"publisher","first-page":"58007","DOI":"10.18632\/oncotarget.11157","volume":"7","author":"AR Nam","year":"2016","unstructured":"Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ (2016) Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget 7:58007\u201358021. https:\/\/doi.org\/10.18632\/oncotarget.11157","journal-title":"Oncotarget"},{"key":"2706_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/1471-2407-10-631","volume":"10","author":"Y Pignochino","year":"2010","unstructured":"Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F (2010) Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10:631. https:\/\/doi.org\/10.1186\/1471-2407-10-631","journal-title":"BMC Cancer"},{"key":"2706_CR30","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-04-2603","volume":"11","author":"K Kiguchi","year":"2005","unstructured":"Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, Digiovanni J (2005) Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res 11:5572\u20135580. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2603","journal-title":"Clin Cancer Res"},{"key":"2706_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J Ruschoff","year":"2012","unstructured":"Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25:637\u2013650. https:\/\/doi.org\/10.1038\/modpathol.2011.198","journal-title":"Mod Pathol"},{"key":"2706_CR32","unstructured":"WHO Classification of Tumours Editorial Board (2019) Digestive system tumours. World Health Organization"},{"key":"2706_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1055\/s-0042-103498","volume":"54","author":"E Czink","year":"2016","unstructured":"Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jager D, Frohling S, Springfeld C (2016) Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer. Z Gastroenterol 54:426\u2013430. https:\/\/doi.org\/10.1055\/s-0042-103498","journal-title":"Z Gastroenterol"},{"key":"2706_CR34","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12885-015-1479-3","volume":"15","author":"S Borgquist","year":"2015","unstructured":"Borgquist S, Zhou W, Jirstrom K, Amini RM, Sollie T, Sorlie T, Blomqvist C, Butt S, Warnberg F (2015) The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer 15:468. https:\/\/doi.org\/10.1186\/s12885-015-1479-3","journal-title":"BMC Cancer"},{"key":"2706_CR35","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2559.2006.02403.x","volume":"48","author":"K Park","year":"2006","unstructured":"Park K, Han S, Kim HJ, Kim J, Shin E (2006) HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48:702\u2013707. https:\/\/doi.org\/10.1111\/j.1365-2559.2006.02403.x","journal-title":"Histopathology"},{"key":"2706_CR36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, Lopez-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Ruschoff J (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476\u2013484. https:\/\/doi.org\/10.1007\/s10120-014-0402-y","journal-title":"Gastric Cancer"},{"key":"2706_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12029-017-9921-1","volume":"49","author":"P Rajadurai","year":"2018","unstructured":"Rajadurai P, Fatt HK, Ching FY (2018) Prevalence of HER2 positivity and its clinicopathological correlation in locally advanced\/metastatic gastric cancer patients in Malaysia. J Gastrointest Cancer 49:150\u2013157. https:\/\/doi.org\/10.1007\/s12029-017-9921-1","journal-title":"J Gastrointest Cancer"},{"key":"2706_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/j.1440-1827.2012.02862.x","volume":"62","author":"S Kiyose","year":"2012","unstructured":"Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, Konno H, Ogura H, Shinmura K, Hattori N, Sugimura H (2012) Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathol Int 62:728\u2013734. https:\/\/doi.org\/10.1111\/j.1440-1827.2012.02862.x","journal-title":"Pathol Int"},{"key":"2706_CR39","first-page":"4207","volume":"34","author":"Y Kimura","year":"2014","unstructured":"Kimura Y, Oki E, Yoshida A, Aishima S, Zaitsu Y, Ohtsu H, Ando K, Ida S, Saeki H, Morita M, Kusumoto T, Oda Y, Maehara Y (2014) Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer. Anticancer Res 34:4207\u20134212","journal-title":"Anticancer Res"},{"key":"2706_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/bjc.1991.243","volume":"64","author":"NR Lemoine","year":"1991","unstructured":"Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, McLelland E, Gullick WJ, Filipe MI (1991) Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 64:79\u201383. https:\/\/doi.org\/10.1038\/bjc.1991.243","journal-title":"Br J Cancer"},{"key":"2706_CR41","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/onc.2017.382","volume":"37","author":"Q Liu","year":"2018","unstructured":"Liu Q, Kulak MV, Borcherding N, Maina PK, Zhang W, Weigel RJ, Qi HH (2018) A novel HER2 gene body enhancer contributes to HER2 expression. Oncogene 37:687\u2013694. https:\/\/doi.org\/10.1038\/onc.2017.382","journal-title":"Oncogene"},{"key":"2706_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"2706_CR43","first-page":"1034","volume":"51","author":"Y Yonemura","year":"1991","unstructured":"Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 51:1034\u20131038","journal-title":"Cancer Res"},{"key":"2706_CR44","first-page":"1207","volume":"19","author":"JK Roh","year":"1992","unstructured":"Roh JK, Paik S, Chung HC, Yang W, Kim HK, Choi IJ, Kim J, Koh E, Lee KS, Min JS et al (1992) Overexpression of erbB-2 protein in gastric adenocarcinoma--a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. Gan To Kagaku Ryoho 19:1207\u20131219","journal-title":"Gan To Kagaku Ryoho"},{"key":"2706_CR45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"key":"2706_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","volume":"8","author":"M Javle","year":"2015","unstructured":"Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB (2015) HER2\/neu-directed therapy for biliary tract cancer. J Hematol Oncol 8:58. https:\/\/doi.org\/10.1186\/s13045-015-0155-z","journal-title":"J Hematol Oncol"},{"key":"2706_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CMAR.S55091","volume":"9","author":"S Sorscher","year":"2013","unstructured":"Sorscher S (2013) Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer Manag Res 9:1\u20133. https:\/\/doi.org\/10.2147\/CMAR.S55091","journal-title":"Cancer Manag Res"},{"key":"2706_CR48","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1200\/JCO.2012.42.3061","volume":"30","author":"LY Law","year":"2012","unstructured":"Law LY (2012) Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J Clin Oncol 30:e271\u2013e273. https:\/\/doi.org\/10.1200\/JCO.2012.42.3061","journal-title":"J Clin Oncol"},{"key":"2706_CR49","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","volume":"64","author":"RK Ramanathan","year":"2009","unstructured":"Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR (2009) A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64:777\u2013783. https:\/\/doi.org\/10.1007\/s00280-009-0927-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"2706_CR50","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, Hiraoka N, Ojima H, Shimada K, Okusaka T, Kosuge T, Miyagawa S, Shibata T (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003\u20131010. https:\/\/doi.org\/10.1038\/ng.3375","journal-title":"Nat Genet"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-019-02706-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-019-02706-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-019-02706-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T00:45:24Z","timestamp":1607820324000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-019-02706-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,14]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2706"],"URL":"https:\/\/doi.org\/10.1007\/s00428-019-02706-6","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,14]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tissues were used in accordance with the ethical regulations of the NCT tissue bank established by the local ethics committee (Ethics Committee of the Medical Faculty of Heidelberg University, approval code S-207\/2015).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PS received funding for grants, boards, and presentations from Novartis. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}